The Pharma Data

MARCH 30, 2021

Novartis Oncology continues to reimagine cancer care through development of robust radioligand therapy portfolio. We continue to invest in radioligand therapy as one of the four unique platforms of Novartis Oncology. Broad expression of FAP demonstrated in tumors or in tumor stroma across many solid tumors 1 ,2 ,3.

Therapies 52

Therapies Licensing Licensing Protein Expression 52

The Pharma Data

OCTOBER 27, 2021

NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. Small molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders. About Teva.

Licensing 52

Licensing Licensing Disease Small Molecule 52

Drug Hunter

JUNE 25, 2023

This edition includes Maze’s glycogen synthase 1 (GYS1) inhibitors that were recently licensed to Sanofi, allosteric androgen receptor (AR) modulators that may be of interest to targeted protein degradation researchers, and brain-penetrant HER2 and ROCK2 inhibitors.

Targeted Protein Degradation 130

Targeted Protein Degradation Computational Chemistry Trials Licensing 130

The Pharma Data

SEPTEMBER 21, 2020

Investors include SV Health Investors and Cancer Research UK. A biotech company spun out of the University of Edinburgh will utilise research to develop new gene therapies to target different types of cancer. I am delighted to be leading such an exciting company,” said Dr Bekkali. Source link.

Therapies 52

Therapies Cell Biology Licensing Licensing 52

LifeSciVC

JULY 17, 2024

We are building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis that originated at Genzyme and then continued at Sanofi, where our founding scientists discovered first-in-class correctors that in preclinical studies directly stabilized the first nucleotide-binding domain (NBD1) of the CFTR protein.

Clinical Research 69

Clinical Research Disease Research Clinical Trials 69

Drug Target Review

MARCH 17, 2025

However, a deeper understanding of brain function particularly the role of synaptic plasticity is now opening the door to innovative therapies. Prior to this, he held the position of Vice President, overseeing various research functions responsible for identifying new targets, technologies and programme development through Phase II.

Treatment 52

Treatment Licensing Licensing Science 52

The Pharma Data

JANUARY 25, 2021

a biotechnology company developing cell and gene therapy treatments for patients suffering from vascular disease, today announced that it raised up to $5.5M that will lead clinical testing of a novel gene therapy for a serious vascular disease in Europe. MIAMI, Jan. 25, 2021 (GLOBE NEWSWIRE) — Ambulero, Inc. ,

Therapies 52

Therapies Disease Licensing Licensing 52

Conversations in Drug Development Trends

OCTOBER 26, 2022

Having worked in psychedelic research since the advent of industry-sponsored trials, Worldwide Clinical Trials has amassed the expertise needed to execute these studies successfully, recently sharing insights in a webinar titled “ Demystifying Complex Operations in Psychedelic Research ,” available on-demand now.

Trials 97

Trials Clinical Trials Licensing Licensing 97

The Pharma Data

JANUARY 4, 2021

Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target. 05, 2021 (GLOBE NEWSWIRE) — ViGeneron GmbH , a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. .

Therapies 52

Therapies Virus Disease Licensing 52

Crown Bioscience

MAY 4, 2021

Crown Bioscience Director Mike Batey takes a closer look at pediatric cancer and how recent regulatory changes and additional research focus may deliver new therapies for kids. Unfortunately, children have limited access to novel therapies, and new drugs for adults are often only tested in children many years following approval.

Research 52

Research Pharmaceutical Companies Licensing Licensing 52

Drug Target Review

DECEMBER 11, 2024

As a contract research organisation, we have supported numerous clients in overcoming matrix interference, particularly small and emerging biotherapeutics developers who may lack the in-house expertise to navigate such complex problems. This highlights its vital role in modern biotherapeutic research.

International 52

International Laboratories Drugs Pharmacokinetics 52

The Pharma Data

AUGUST 17, 2020

Bristol Myers Squibb intends to advance the research and development of DF6002 in oncology and hematology. “As Executive Vice President & President, Research & Early Development, Bristol Myers Squibb. About Bristol Myers Squibb. About Dragonfly. Bristol Myers Squibb Cautionary Statement Regarding Forward-Looking Statements.

Licensing 52

Licensing Licensing Production Clinical Trials 52

The Pharma Data

MAY 7, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine. The Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

New Drug Approvals

APRIL 2, 2025

acting director of the FDA’s Center for Drug Evaluation and Research. The application received Breakthrough Therapy , Fast Track and Priority Review designations by the FDA. 8] In preliminary research, suzetrigine had no serious neurological, behavioral, or cardiovascular effects. [3] under nitrogen. ESI-MS m/z calc.475.0922,

FDA 62

FDA Therapies Trials Treatment 62

The Pharma Data

JANUARY 3, 2021

(Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced that U.S. GM1 is a rare and often life-threatening CNS disorder with no approved disease-modifying therapies available. About PBGM01.

Therapies 52

Therapies FDA Treatment Clinical Trials 52

The Pharma Data

NOVEMBER 1, 2020

Corlieve’s lead program employs a novel AAV gene therapy approach for the treatment of refractory temporal lobe epilepsy (TLE), the most commonly diagnosed focal epilepsy in humans. Maryland , US), a leading gene therapy company. Maryland , US), a leading gene therapy company. PARIS , Nov.

Therapies 52

Therapies Science Treatment Disease 52

The Pharma Data

NOVEMBER 4, 2020

(TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing 40

Licensing Licensing Production Engineering 40

The Pharma Data

JUNE 14, 2023

Global Head of Research and Early Development for Oncology, Pharmaceuticals Division, Bayer AG. With our oncology strategy, we are dedicated to accelerating the research and development of novel cancer therapies that have the potential to make a meaningful difference in the lives of patients.”

Licensing 40

Licensing Licensing Small Molecule Science 40

The Pharma Data

DECEMBER 20, 2020

Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties.

Licensing 40

Licensing Licensing Pharmaceuticals Pharmaceutical Companies 40

The Pharma Data

MAY 2, 2022

– Gilead to License Exclusive Worldwide Rights to the Investigational Candidate DF7001, a 5T4-Targeting NK Cell Engager for Solid Tumors –. – Gilead to Have Options to License Several Additional NK Cell Engager Programs –. Gilead Sciences, Inc. About Dragonfly. Dragonfly Therapeutics, Inc.

Licensing 52

Licensing Licensing Research Protein Expression 52

FDA Law Blog: Drug Discovery

JANUARY 4, 2023

Brevig, Senior Regulatory Device and Biologics Expert — On December 7, 2022, FDA’s Center for Biologics Evaluation and Research (CBER) and the Office of Tissues and Advanced Therapies (OTAT) held a town hall to answer questions related to cell therapy and tissue-engineered products chemistry, manufacturing, and contr­­ols (CMC).

Therapies 59

Therapies Engineering Production FDA 59

The Pharma Data

MARCH 30, 2021

Kesimpta is a targeted, precisely dosed and delivered B-cell therapy that has shown superior efficacy with a similar safety profile compared with teriflunomide, a first-line treatment in MS 2. Ofatumumab was originally developed by Genmab and licensed to GlaxoSmithKline. About Kesimpta ® (ofatumumab).

Therapies 52

Therapies Treatment Disease Licensing 52

The Pharma Data

DECEMBER 21, 2020

The FDA granted cilta-cel Breakthrough Therapy and Orphan Drug designations in 2019, and the therapy received a PRIME Priority Medicines designation from the European Commission (EC) that same year and an Orphan Drug designation from the EC in February 2020. Cilta-cel also won a Breakthrough Therapy designation in China in August.

Therapies 40

Therapies Licensing Licensing Clinical Development 40

The Pharma Data

JUNE 7, 2022

Nasdaq: BIIB) — Biogen and Alectos Therapeutics have entered into a license and collaboration agreement to develop and commercialize a novel preclinical selective GBA2 inhibitor, AL01811, which has first-in-class potential as an oral disease modifying treatment for patients with Parkinson’s disease (PD). Biogen Inc.

Licensing 40

Licensing Licensing Small Molecule Disease 40

The Pharma Data

SEPTEMBER 2, 2020

The primary drive of the deal for Gilead is to secure exclusive licensing rights to Jounce’s JTX-1811, a monoclonal antibody which targets the chemokine receptor CCR88 to selectively deplete immunosuppressive tumour-infiltration T regulatory (TITR) cells. From that point, Gilead will take over development as the sole license holder. “We

Licensing 52

Licensing Licensing Therapies Treatment 52

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China.

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

Drug Target Review

APRIL 4, 2024

The animal model is based on creating a dopamine-deficient state, by a specific lesion of dopaminergic cells, and then exposing it to repeated substitution therapy with L-DOPA. Between 1995 and 2000, he was managing research collaborations between the University and Pharma Industry partners. In 1998, he co-founded Carlsson Research.

Disease 106

Disease Treatment Licensing Licensing 106

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). . TOKYO and CAMBRIDGE, England , Dec. GPCR – G protein-coupled receptors.

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

LifeSciVC

JANUARY 16, 2024

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. recent announcements from Merck and Sanofi for obesity and broader metabolic disease). Join the club.

Small Molecule 140

Small Molecule Trials Therapies Disease 140

The Pharma Data

NOVEMBER 17, 2020

Lead Pharma has entered into a collaboration and license agreement with Roche , hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases. . This includes therapies against the nuclear receptor ROR?t, Source link.

Small Molecule 52

Small Molecule Disease Immune Response Licensing 52

DrugBank

OCTOBER 4, 2024

This involves assessing the strength and breadth of patents, evaluating the potential for future patent challenges, and analyzing the value derived from licensing agreements and royalty streams. However, such acquisitions also entail significant risks for biotech firms.

Pharmaceuticals 98

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 98

The Pharma Data

JUNE 28, 2021

Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA small molecule for the treatment of prostate cancer. Lisa Placanica, Senior Managing Director Center for Technology Licensing at Weill Cornell Medicine. Noria) and PSMA Therapeutics Inc.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52

Conversations in Drug Development Trends

NOVEMBER 27, 2023

Food and Drug Administration (FDA) announced its acceptance of the Biologics License Application (BLA) for exa-cel. In recognition of the unmet need and medical urgency for innovative therapies in the sickle cell space, the FDA granted exa-cel Priority Review, with a formal decision expected by December 8, 2023.

Treatment 75

Treatment FDA Clinical Trials Therapies 75

The Pharma Data

MARCH 22, 2022

Co-founded at Fred Hutchinson Cancer Research Center with Phil Greenberg, M.D., With proceeds from this backing, the company will operationalize its platform discovery machine and seek to drive multiple oncogene motorist programs into the clinic while pursuing reciprocal technology licenses to bolster its cell remedy platform.

Therapies 52

Therapies Engineering Treatment Licensing 52

The Pharma Data

DECEMBER 14, 2020

Harbour BioMed (HBM) announced with Utrecht University on Monday that they have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its program to AbbVie. Preclinical research suggests that this antibody against the target can potentially address the existing pandemic, as well as escape mutants. .

Licensing 52

Licensing Licensing Pharmacokinetics Clinical Trials 52

The Pharma Data

NOVEMBER 25, 2020

BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively. About BioInvent.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

DECEMBER 29, 2020

a biotechnology company developing cell therapies that enable organ regeneration, announced today that the U.S Under the IND, LyGenesis will be conducting a Phase 2a study on the safety, tolerability, and efficacy of its first-in-class novel cell therapy for patients with end stage liver disease (ESLD). and Longevity Vision Fund.

Therapies 40

Therapies FDA Trials Disease 40